Results 181 to 190 of about 1,505,630 (287)

Targeting amyloid-β pathology by chimeric antigen receptor astrocyte (CAR-A) therapy. [PDF]

Science
Chen Y, Liu Y, Nguyen K, Wu J, Song S, Lin K, Rodrigues PF, Du S, Zhou C, Xiong K, Bosch M, Lin PB, Khantakova D, Wu S, Wu M, Yuede C, Holtzman DM, Colonna M.   +17 more
europepmc   +1 more source

Cell and Gene Therapies Manufacturing Challenges and Integrated Good Manufacturing Practices Solutions: A Lifecycle Perspective

Biotechnology and Bioengineering, EarlyView.
Lifecycle perspective on cell and gene therapy manufacturing challenges and enabling GMP solutions. ABSTRACT Cell and gene therapies (CGTs) are revolutionizing modern medicine; however, making these advanced medicines scalable and readily available to commercial manufacturers worldwide is a major challenge. The number of approved CGT products continues
Rajath Samaga, Udisha Singh, Sachin Dattram Pawar   +2 more
wiley   +1 more source

CHIMERIC ANTIGEN RECEPTOR T CELLS: PAST, PRESENT, AND FUTURE

Chimeric antigen receptor T (CAR T) therapy, a type of anticancer cellular immunotherapy, is emerging expeditiously. Primarily reported in 1987, the concept of a chimeric T-cell receptor (TCR), which combines antibody-derived variable regions with TCR ...
BM, NAGARAJ, DP, SHRUTHI
core   +1 more source

Editorial: Novel chimeric antigen receptor (CAR) designs in engineering NK cells for cancer. [PDF]

Front Immunol
Chan WK.
europepmc   +1 more source

Reprogramming tumor immune microenvironment by ultrasound‐responsive nanoplatforms for enhanced cancer immunotherapy

BMEMat, EarlyView.
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao, Rui Qu, Zan Dai, Xiqun Jiang, Xu Zhen   +4 more
wiley   +1 more source

Development of Chimeric Antigen Receptor-Modified NK Cells for the Immunotherapy of Adult T-Cell Leukemia/Lymphoma. [PDF]

Eur J Haematol
Uchida Y, Tateo S, Wakao M, Shinchi H, Sawayama H, Fukumoto A, Yoshimitsu M, Suda Y.   +7 more
europepmc   +1 more source

Ultrasmall Fe‐curcumin immunomodulators reinvigorate CAR‐T cells to potentiate solid tumor immunotherapy by mitigating cell exhaustion and senescence

BMEMat, EarlyView.
This work discovered a novel research that ultrasmall Fe‐curcumin immunomodulators could reinvigorate CAR‐T cells to potentiate solid tumor immunotherapy by mitigating cell exhaustion and senescence. Abstract CAR‐T cell immunotherapy has achieved exciting success in hematologic malignancies, but the therapeutic efficacy is relatively limited in solid ...
Jiazhi Duan, Yuchan Xue, Miao Zhang, Zihao Zhang, Shiyu Peng, Minghao Sui, Han Ding, Yingying Nie, Yuemin Feng, Le Wang, Tianru Zhang, Mingchuan Yu, He Xia, Hong Liu, Qiang Zhu, Songbo Zhao   +15 more
wiley   +1 more source

Auto-inducible expression of chimeric antigen receptor T cells using the NR4A1 promoter. [PDF]

Immunol Cell Biol
Smith-Bell SW, Halpin JC, Darcy PK, Liyanage T, Dobson LJ, McLellan AD.   +5 more
europepmc   +1 more source

Real time in vivo efficacy monitoring of desialylation and perforation enhanced immunotherapy of cancer

BMEMat, EarlyView.
A multifunctional nanomedicine is designed to engineer NK cells for enhanced cancer immunotherapy through perforation and desialylation, enabling real‐time monitoring of ATP and GrB levels for precise efficacy assessment. Abstract Efficient enhanced NK cell therapy is of critical importance in the immune treatment of cancer.
Yuanjiao Yang, Yuru Wang, Xuemei Li, Chaoyi Yang, Yuhui Yang, Yanyun Fang, Lin Ding, Yunlong Chen, Huangxian Ju   +8 more
wiley   +1 more source

Development and characterization of anti-CXCR4 chimeric antigen receptor T cells. [PDF]

Transl Oncol
Seir G, Bubb QR, Sotillo E, Gruber T, Richards RM, Czechowicz A.   +5 more
europepmc   +1 more source